DrugPatentWatch Database Preview
Larotrectinib sulfate - Generic Drug Details
What are the generic drug sources for larotrectinib sulfate and what is the scope of freedom to operate?
Larotrectinib sulfate
is the generic ingredient in one branded drug marketed by Bayer Hlthcare and Bayer Healthcare, and is included in two NDAs. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.Larotrectinib sulfate has one hundred and thirty-six patent family members in forty-one countries.
Two suppliers are listed for this compound.
Summary for larotrectinib sulfate
| International Patents: | 136 |
| US Patents: | 12 |
| Tradenames: | 1 |
| Applicants: | 2 |
| NDAs: | 2 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 17 |
| Patent Applications: | 31 |
| DailyMed Link: | larotrectinib sulfate at DailyMed |
Synonyms for larotrectinib sulfate
| (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide sulfate |
| 1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-, sulfate (1:1) |
| 1-Pyrrolidinecarboxamide, N-[5-[(2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxy-, (3S)-, sulfate (1:1) |
| 1223405-08-0 |
| ARRY-470 |
| ARRY-470 sulfate |
| CHEMBL3989939 |
| CS-5314 |
| D11138 |
| HY-12866A |
| Larotrectinib (LOXO-101) sulfate |
| Larotrectinib sulfate (USAN) |
| Larotrectinib sulfate [USAN] |
| LOXO-101 (sulfate) |
| LOXO-101 sulfate |
| LOXO-101(sulfate) |
| PXHANKVTFWSDSG-QLOBERJESA-N |
| RDF76R62ID |
| s7960 |
| SCHEMBL2239598 |
| UNII-RDF76R62ID |
US Patents and Regulatory Information for larotrectinib sulfate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Healthcare | VITRAKVI | larotrectinib sulfate | SOLUTION;ORAL | 211710-001 | Nov 26, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Bayer Hlthcare | VITRAKVI | larotrectinib sulfate | CAPSULE;ORAL | 210861-001 | Nov 26, 2018 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Bayer Hlthcare | VITRAKVI | larotrectinib sulfate | CAPSULE;ORAL | 210861-002 | Nov 26, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Bayer Hlthcare | VITRAKVI | larotrectinib sulfate | CAPSULE;ORAL | 210861-001 | Nov 26, 2018 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Bayer Hlthcare | VITRAKVI | larotrectinib sulfate | CAPSULE;ORAL | 210861-002 | Nov 26, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for larotrectinib sulfate
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Israel | 212341 | Start Trial |
| Taiwan | I577680 | Start Trial |
| Slovenia | 2350071 | Start Trial |
| Peru | 20181888 | Start Trial |
| Norway | 3106463 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
